The Open UniversitySkip to content
 

Radiolabelled aptamers for imaging and therapy

Perkins, A. C. and Missailidis, S. (2005). Radiolabelled aptamers for imaging and therapy. In: International Conference on Radiopharmaceutical Therapy, 11-14 Oct 2005, Limasol, Cyprus.

Google Scholar: Look up in Google Scholar

Abstract

Advances in biotechnology have led to new techniques for the design, selection and production of ligands suitable for molecular targeting. One promising approach is the production of specific receptor binding molecules based on defined nucleic acid sequences that are capable of recognising a wide array of target molecules. These oligonuclide ligands are known as aptamers. The technology that allows production of aptamer molecules is known as systematic evolution of ligands by exponential enrichment (SELEX). Using these techniques, aptamers can now be produced rapidly, inexpensively, and with high homogeneity. Furthermore, they are stable over long term storage at ambient room temperatures. A monomeric aptamer is small in size, with a molecular weight as low as 5 to 10 kDa. However, the aptamer molecule may be used as building block for custom designed targeting agents, offering several advantages. These molecules penetrate tumour readily, reach peak levels quickly and clear from the body rapidly, thus having properties of low toxicity and immunoreactivity. Previous work with radiolabelled aptamers is limited and is currently restricted to preclinical studies, but the body of evidence is steadily growing and aptamers are emerging as valuable clinical products for diagnostic imaging and therapy. We have shown that aptamers directed against the mucin 1 (MUC1) antigen, a tumour marker previously extensively used in tumour imaging and therapy, demonstrated high specificity and uniform penetration in tumour xenografts. The future strategy will be to manipulate the molecular weight of the molecules to achieve an optimum balance between the low immunogenicity and excellent tumour penetration for diagnostic imaging and targeted therapy. In this way, a balance can be achieved between the rapid renal clearance and adequate tumour uptake required for diagnostic imaging and targeted therapy.

Item Type: Conference Item
Copyright Holders: 2005 Not known
Extra Information: The Quarterly journal of nuclear medicine and molecular imaging
2007, vol. 51, no4, pp. 292-296
1824-4785
Keywords: aptamers; peptides; radiopharmaceuticals; neoplasms;
Academic Unit/Department: Science > Life, Health and Chemical Sciences
Interdisciplinary Research Centre: Biomedical Research Network (BRN)
Related URLs:
Item ID: 26108
Depositing User: Sotiris Missailidis
Date Deposited: 15 Jun 2011 09:36
Last Modified: 10 Mar 2014 10:31
URI: http://oro.open.ac.uk/id/eprint/26108
Share this page:

Actions (login may be required)

View Item
Report issue / request change

Policies | Disclaimer

© The Open University   + 44 (0)870 333 4340   general-enquiries@open.ac.uk